SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today provided additional context regarding its previously announced proposal to change the Company’s jurisdiction of incorporation from Alberta, Canada, to the State of Nevada in the United States. The Company believes it is important to clearly communicate the strategic and operational reasons underlying this proposal as Oncolyt ...

PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Provides Potential Pathway to Accelerated Approval of PDS0101 PRINCETON, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company has submitted a protocol amendment to the U.S. Food & Drug Administration (“FDA”) ...

BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that Chief Executive Officer Ivor Elrifi will deliver a corporate presentation at the 9th Annual Neuroscience Innovation Forum, organized by Sachs Associates. The presentation is scheduled for 2:00 PM PT on January 11, 2026, at the Marines' Memorial Club in San Francisco, Californi ...

IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparator IM1240's pharmacokinetic profile showed increased systemic exposure and a prolonged circulating half-life enabled by its human serum albumin moiety and capping design IM1240 on track towards first-in-human clinical trials, with regulatory submission planned for the second half of 2026 REHOVOT, Israel, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) ( ...

Core Viewpoint - Innate Pharma SA has released its total number of shares outstanding and voting rights as of December 31, 2025, in compliance with French regulatory requirements [1]. Group 1 - The total number of shares outstanding for Innate Pharma SA is 93,719,323 ordinary shares [1]. - The announcement is made in accordance with article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation [1].

-Coherus Oncology formally introduces non-proprietary name: tagmokitug- -Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical studies- -Data show CCR8 target is present with high prevalence and density in many solid tumors- REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced the publication of preclinical and clinical biomarker research in Molecular Cancer Therapeutics describing ...

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, confirms the planned announcement of the results from cohort 4 of the randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis in the second half of January 2026. Given the proximity to our upcoming data, we are cancelling all previously planned conference attendances, includ ...

Core Insights - BioVaxys Technology Corp. has integrated the DPX™ platform into its operations, focusing on organic growth and innovative vaccine development that enhances immune response through a novel mechanism of action [1][5]. Company Developments - The company appointed Dr. James Tartaglia and Dr. Marianne Stanford to its Board and as Scientific Advisor, respectively, enhancing its scientific and business development expertise [2][3][4]. - Dr. Tartaglia has over 34 years of experience in vaccine R&D, having led vaccine development at Sanofi, while Dr. Stanford previously led the development of the DPX™ vaccine portfolio at IMV Inc [3][4]. Clinical Studies - BioVaxys reported positive results from a Phase 1 study of maveropepimut-S (MVP-S) in HR+/HER2- stage II-III breast cancer, showing a significant immune response and a decrease in Ki67 levels from a median of 24% to 6% post-treatment [7][8]. - The company plans to further evaluate MVP-S's systemic immunity and pursue a Phase II study to modify the tumor immune environment in high-risk HR+ breast cancer [9]. Collaborations and Licensing - BioVaxys entered a research agreement with Sona Nanotech to develop new cancer therapeutics combining the DPX platform with Sona's Targeted Hyperthermia Therapy™ [10]. - The company is exploring out-licensing opportunities for MVP-S, particularly for ovarian cancer, and is in discussions with a global pharma company [11][12]. Pipeline Expansion - BioVaxys is advancing its early-stage pipeline with multiple out-licensing opportunities and research collaborations, including a DPX formulation for rabies and a DPX-RSV vaccine that demonstrated antigen-specific immune responses in 93% of subjects [6][14]. - The company is also developing additional infectious disease programs, including DPX-rHA/DPX-FLU for influenza and DPX-rPA for anthrax, with promising preclinical results [15]. Revenue Generation - BioVaxys has revenue-generating licenses with Zoetis Inc. and SpayVac for Wildlife, Inc., focusing on vaccines in the animal health field, with ongoing progress towards commercialization [17][18]. - SpayVac has initiated the regulatory approval process for its immunocontraceptive vaccine targeting feral horses and deer populations, which is based on BioVaxys's technology [18][20]. Future Outlook - The company anticipates aggressive business development activity in 2026, aiming to advance ongoing out-licensing and research collaboration discussions, and to book its first royalty income [22].

Core Insights - IMUNON, Inc. is making significant progress towards a potential breakthrough in ovarian cancer treatment with its immunotherapy candidate IMNN-001, as evidenced by advancements in the Phase 3 OVATION 3 Study and promising data from the MRD study [1][2][3]. Group 1: Clinical Progress - The Phase 3 OVATION 3 Study is evaluating IMNN-001 in combination with standard chemotherapy for newly diagnosed advanced ovarian cancer, with strong enrollment interest from the medical community [2]. - In the Phase 2 OVATION 2 Study, IMNN-001 demonstrated a 13-month extension in median overall survival (OS) with a hazard ratio of 0.70, and in patients receiving PARP inhibitors, the median OS has not yet been reached, with many patients surpassing five years of follow-up [2]. - The ongoing MRD study shows encouraging preliminary results, including lower MRD positivity rates and higher complete response scores compared to the control arm [4]. Group 2: Immunotherapy Insights - IMNN-001 has shown a broad impact on the tumor microenvironment, leading to IL-12 production by macrophages, which enhances T cell cytotoxic functions [3][7]. - The treatment has resulted in a more inflamed tumor immune microenvironment, effectively converting "cold" tumors to "hot" tumors, thereby activating both innate and adaptive immune systems [7]. Group 3: Financial and Strategic Position - The company has maintained financial discipline throughout 2025, with significant cost reductions in cGMP-compliant manufacturing, positioning for high gross margins upon potential FDA approval [9]. - IMUNON is committed to funding the OVATION 3 trial, with an estimated budget of $30 million for the HRD+ subgroup focus, indicating a strategic approach to clinical development [9]. Group 4: Future Outlook - Looking ahead to 2026, IMUNON is poised for key milestones, including continued enrollment in OVATION 3 and potential early stopping for BLA filing in the HRD+ population [10]. - The company anticipates additional data presentations at major conferences and further insights from OVATION 2 tumor samples, reinforcing its commitment to advancing cancer care [10].

Core Insights - IMUNON, Inc. is making significant progress towards a potential breakthrough in ovarian cancer treatment with its immunotherapy candidate IMNN-001, as evidenced by advancements in the Phase 3 OVATION 3 Study and promising data from the MRD study [1][2][3] Group 1: Clinical Progress - The Phase 3 OVATION 3 Study is evaluating IMNN-001 in combination with standard chemotherapy for newly diagnosed advanced ovarian cancer, with strong enrollment interest from the medical community [2] - IMNN-001 demonstrated a 13-month extension in median overall survival (OS) in the Phase 2 OVATION 2 Study, with a hazard ratio of 0.70, and patients receiving PARP inhibitors showed a median OS not yet reached after over 31 months of follow-up [2] - The ongoing MRD study shows lower MRD positivity rates and higher complete response scores with IMNN-001 compared to the control arm, indicating its potential effectiveness [4] Group 2: Mechanism of Action - IMNN-001 induces IL-12 production in macrophages, enhancing T cell cytotoxic functions and remodeling the tumor microenvironment to activate both innate and adaptive immune systems [7][8] - The treatment leads to a more inflamed tumor microenvironment, effectively converting "cold" tumors to "hot" tumors, which is crucial for immunotherapy effectiveness [7] Group 3: Financial and Strategic Position - The company maintained financial discipline in 2025, with an estimated $30 million budget for the OVATION 3 trial, focusing on the HRD+ subgroup [9] - Cost reductions from cGMP-compliant manufacturing may lead to high gross margins upon potential FDA approval, reflecting growing confidence from institutional investors [9] Group 4: Future Outlook - IMUNON is poised for key milestones in 2026, including continued enrollment in OVATION 3 and potential early stopping for BLA filing in the HRD+ population [10] - The company anticipates additional data presentations and progress on business development initiatives, with Fast Track and Orphan Drug designations in place [10]